CIK 0001124105 · Accelerated filer<br>Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 562020050
- Phone
- (858) 284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-05 | Luo Ying Chief Executive Officer | Sale 10b5-1 | −179 | $8.01 | $1K | 2,575,362 |
| 2026-05-04 | GNI Group Ltd. 10% owner | Other acquisition · Series B Preferred Stock | +458,120 | 458,120 | ||
| 2026-05-04 | GNI Group Ltd. 10% owner | Other acquisition · Series B Preferred Stock | +2,143,706 | 2,143,706 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +95,060 | 95,060 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +47,530 | 47,530 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +11,882 | 11,882 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +33,271 | 33,271 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +95,060 | 95,060 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +92,683 | 92,683 | ||
| 2026-05-04 | Eastling Thomas Wilson Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +33,271 | 33,271 | ||
| 2026-01-07 | Zhang Ping Director | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-01-07 | Chen Ruoyu Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2025-08-18 | Weng Dan Director | Grant or award · Stock Option (Right to Buy) | +52,000 | 52,000 | ||
| 2025-08-05 | Zhang Ping Director | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-06-04 | Eastling Thomas Wilson Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2025-06-04 | Epstein David M. Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2025-06-04 | Nussbaum Rodney L Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2025-06-04 | Parry Renate Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2025-06-04 | Carmichael Gordon Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2025-05-28 | Ma Songjiang President | Sale 10b5-1 | −558 | $10.07 | $6K | 2,806,084 |
Page 4 of 11 · 215 trades